H.R. 3334 118th Congress
STOP CCP Act
- International Affairs
- Sponsor: Lisa C. McClain
- Congress.gov ↗
Latest action, Nov 12, 2024: Received in the Senate and Read twice and referred to the Committee on Foreign Relations.
How the House voted: On Passage
Sep 25, 2024 · Passed · 243–174 (it needed 1/2)
- Yea (243)
- Nay (174)
- Didn't vote (15)
- Letters: party (D, R, I)
By party
- Democrat
- Republican
- Independent
Every roll call on it (2)
Each dot is a roll call, in order: how much of the House voted yea. The ringed one decided it.
- Carried
- Failed
See the data
| Date | Question | Result | Yea–nay |
|---|---|---|---|
| Sep 25, 2024 | On Passage | Passed | 243–174 |
| Sep 25, 2024 | On Agreeing to the Amendment | Agreed to | 419–1 |
9 cosponsors
Sponsored by Lisa C. McClain (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
2 D · 7 R
- Democrat
- Republican
- Independent
Referred to: Senate: Foreign Relations Committee; House: Foreign Affairs Committee; House: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
3 reports
1 report
1 report
All 4 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| FDD ACTION | 3 | $390K | Q2 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 1 | $920K | Q4 2024 | Q4 2024 | yes | |
| HERITAGE ACTION FOR AMERICA | 1 | $180K | Q3 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 1 | $7.6M | Q4 2024 | Q4 2024 | yes |